212 related articles for article (PubMed ID: 28943101)
1. Inhibition of Transglutaminase 2 activity increases cisplatin cytotoxicity in a model of human hepatocarcinoma chemotherapy.
Meshram DD; Pike CVS; Coussons PJ
Eur J Pharmacol; 2017 Nov; 815():332-342. PubMed ID: 28943101
[TBL] [Abstract][Full Text] [Related]
2. Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
Carbone C; Di Gennaro E; Piro G; Milone MR; Pucci B; Caraglia M; Budillon A
Amino Acids; 2017 Mar; 49(3):517-528. PubMed ID: 27761756
[TBL] [Abstract][Full Text] [Related]
3. Tissue transglutaminase-mediated chemoresistance in cancer cells.
Verma A; Mehta K
Drug Resist Updat; 2007; 10(4-5):144-51. PubMed ID: 17662645
[TBL] [Abstract][Full Text] [Related]
4. Transglutaminase Is Required for Epidermal Squamous Cell Carcinoma Stem Cell Survival.
Fisher ML; Keillor JW; Xu W; Eckert RL; Kerr C
Mol Cancer Res; 2015 Jul; 13(7):1083-94. PubMed ID: 25934691
[TBL] [Abstract][Full Text] [Related]
5. Transglutaminase-2: evolution from pedestrian protein to a promising therapeutic target.
Agnihotri N; Mehta K
Amino Acids; 2017 Mar; 49(3):425-439. PubMed ID: 27562794
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the JNK signaling pathway increases sensitivity of hepatocellular carcinoma cells to cisplatin by down-regulating expression of P-glycoprotein.
Liu XY; Liu SP; Jiang J; Zhang X; Zhang T
Eur Rev Med Pharmacol Sci; 2016; 20(6):1098-108. PubMed ID: 27049263
[TBL] [Abstract][Full Text] [Related]
7. Transglutaminase 2 expression levels regulate sensitivity to cystamine plus TRAIL-mediated apoptosis.
Jang JH; Park JS; Lee TJ; Kwon TK
Cancer Lett; 2010 Jan; 287(2):224-30. PubMed ID: 19632032
[TBL] [Abstract][Full Text] [Related]
8. Gα(h)/transglutaminase-2 activity is required for maximal activation of adenylylcyclase 8 in human and rat glioma cells.
Obara Y; Yanagihata Y; Abe T; Dafik L; Ishii K; Nakahata N
Cell Signal; 2013 Mar; 25(3):589-97. PubMed ID: 23200849
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanism by which acyclic retinoid induces nuclear localization of transglutaminase 2 in human hepatocellular carcinoma cells.
Shrestha R; Tatsukawa H; Shrestha R; Ishibashi N; Matsuura T; Kagechika H; Kose S; Hitomi K; Imamoto N; Kojima S
Cell Death Dis; 2015 Dec; 6(12):e2002. PubMed ID: 26633708
[TBL] [Abstract][Full Text] [Related]
10. Role of transglutaminase 2 in PAC
Algarni AS; Hargreaves AJ; Dickenson JM
Biochem Pharmacol; 2017 Mar; 128():55-73. PubMed ID: 28065858
[TBL] [Abstract][Full Text] [Related]
11. Implications of tissue transglutaminase expression in malignant melanoma.
Fok JY; Ekmekcioglu S; Mehta K
Mol Cancer Ther; 2006 Jun; 5(6):1493-503. PubMed ID: 16818508
[TBL] [Abstract][Full Text] [Related]
12. The role of TG2 in regulating S100A4-mediated mammary tumour cell migration.
Wang Z; Griffin M
PLoS One; 2013; 8(3):e57017. PubMed ID: 23469180
[TBL] [Abstract][Full Text] [Related]
13. Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis.
Liu T; Tee AE; Porro A; Smith SA; Dwarte T; Liu PY; Iraci N; Sekyere E; Haber M; Norris MD; Diolaiti D; Della Valle G; Perini G; Marshall GM
Proc Natl Acad Sci U S A; 2007 Nov; 104(47):18682-7. PubMed ID: 18003922
[TBL] [Abstract][Full Text] [Related]
14. β
Vyas FS; Nelson CP; Freeman F; Boocock DJ; Hargreaves AJ; Dickenson JM
Eur J Pharmacol; 2017 Oct; 813():105-121. PubMed ID: 28754379
[TBL] [Abstract][Full Text] [Related]
15. Synergism of cisplatin-oleanolic acid co-loaded calcium carbonate nanoparticles on hepatocellular carcinoma cells for enhanced apoptosis and reduced hepatotoxicity.
Khan MW; Zhao P; Khan A; Raza F; Raza SM; Sarfraz M; Chen Y; Li M; Yang T; Ma X; Xiang G
Int J Nanomedicine; 2019; 14():3753-3771. PubMed ID: 31239661
[No Abstract] [Full Text] [Related]
16. Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-kappaB activity in hypoxic tumor cells.
Jang GY; Jeon JH; Cho SY; Shin DM; Kim CW; Jeong EM; Bae HC; Kim TW; Lee SH; Choi Y; Lee DS; Park SC; Kim IG
Oncogene; 2010 Jan; 29(3):356-67. PubMed ID: 19838207
[TBL] [Abstract][Full Text] [Related]
17. A1 adenosine receptor-induced phosphorylation and modulation of transglutaminase 2 activity in H9c2 cells: A role in cell survival.
Vyas FS; Hargreaves AJ; Bonner PL; Boocock DJ; Coveney C; Dickenson JM
Biochem Pharmacol; 2016 May; 107():41-58. PubMed ID: 27005940
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of nuclear factor κB transcription activity drives a synergistic effect of cisplatin and oridonin on HepG2 human hepatocellular carcinoma cells.
Dong X; Liu F; Li M
Anticancer Drugs; 2016 Apr; 27(4):286-99. PubMed ID: 26704389
[TBL] [Abstract][Full Text] [Related]
19. Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling.
Cao L; Petrusca DN; Satpathy M; Nakshatri H; Petrache I; Matei D
Carcinogenesis; 2008 Oct; 29(10):1893-900. PubMed ID: 18667446
[TBL] [Abstract][Full Text] [Related]
20. The complex role of transglutaminase 2 in glioblastoma proliferation.
Gundemir S; Monteagudo A; Akbar A; Keillor JW; Johnson GVW
Neuro Oncol; 2017 Feb; 19(2):208-218. PubMed ID: 27591334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
